Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy

Current Opinion in Immunology

Volumn 13, Issue 4, 2001, Pages 483-488

  Carcelain, G ^a   Debre P ^a   Autran, B ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

HOMEOSTASIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; REDUCTION; REVIEW; T LYMPHOCYTE;

EID: 0035423963     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00245-4     Document Type: Review

References (54)

1. + T cell homeostasis and function in advanced HIV disease
2. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
3. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of Zidovudine, Lamivudine and Ritonavir: Results of AIDS clinical trials group protocol 315
4. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
5. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy
6. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen
7. Initial increase in blood CD4(+) lymphocytes after HIV retroviral therapy reflects redistribution from lymphoid tissues
8. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
9. T-cell changes after combined nucleoside analogue therapy in HIV primary infection
10. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
11. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor containing antiretroviral regiment
12. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
13. Long term immunologic effects and side effects of successful antiretroviral therapy
14. Mathematical modeling of the inter-relationship of CD4 lymphocyte count and viral load changes induced by protease inhibitor indinavir
15. Thymic size and lymphocyte restoration in HIV infected patients following 48 weeks of therapy with zidovudine, lamivudine and ritonavir
16. Factors influencing T-cell turnover in HIV-1 seropositive patients
17. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: Age inversely predicts naive CD4 cell count increase
18. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans
19. + lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle
20. + T cell reactivity to CMV after HAART in an HIV-1 infected patient
21. Perturbation of CD4 and CD8 T cell repertoires during progression to AIDS and influence of antiviral therapy
22. Changes in thymic function with age and during the treatment of HIV infection
23. Direct evidence for thymic function in adult humans
24. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
25. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection
26. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
27. Increased production of IL7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis
28. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
29. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
30. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells
31. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
32. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
33. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
34. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
35. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
36. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team
37. Decline in deaths from AIDS due to new antiretrovirals
38. Combination antiretroviral therapy and incidence of AIDS-related malignancies
39. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
40. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
41. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
42. RESTIMOP (ANRS 078): A multicenter prospective study to evaluate the discontinuation of maintenance therapy for CMV retinitis in HIV-patients receiving HAART
43. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
44. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia
45. + T lymphocytes
46. Immune control of HIV-1 after early treatment of acute infection
47. Maximum suppression of HIV replication leads to the restoration of HIV specific responses in early HIV disease
48. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
49. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
50. + T lymphocytes with changes in viral load
51. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
52. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients
53. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
54. Boosting immunity to HIV - Can the virus help?